Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Issues Letters of Acknowledgement for Infant Formula Transition PlanCFSAN Constituent Updates FDA Issues Letters of Acknowledgement for Infant Formula Transition Plan
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintConstituent Update

January 9, 2023

Today the U.S. Food and Drug Administration (FDA) is announcing that the agency has sent letters of acknowledgement to all manufacturers of infant formula that previously received letters of enforcement discretion for specific infant formula products and have expressed interest in taking steps to remain on the U.S. market. To increase the diversity of those supplying infant formula and support a stable supply of infant formula in the U.S., the FDA is providing a pathway for manufacturers of these infant formula products to continue marketing their products while they work toward meeting all FDA requirements. The agency has updated its web page on enforcement discretion to manufacturers to indicate the 11 companies that have expressed interest in taking these steps.

Under guidance issued in September 2022, infant formula manufacturers currently marketing their products in the U.S. under enforcement discretion were advised to send to the FDA by Dec. 5, 2022, a letter of intent identifying specific infant formula products for which the manufacturer intended to pursue compliance with all regulatory requirements.  The FDA has reviewed the letters of intent and has communicated directly with manufacturers with a letter stating that FDA intends to continue exercising enforcement discretion relating to the importation, sale, and distribution of specific products provided the firm adheres to criteria previously communicated in a letter of enforcement discretion (such as  continued testing for nutrient content and certain pathogens), and the firm continues to make meaningful progress as described in the September 2022 guidance toward compliance with applicable regulatory requirements for these products. The guidance provides a timetable for the actions manufacturers will be taking to comply with all applicable requirements.

The FDA hosted four industry webinars to provide an overview and answer questions on the recently released guidance to infant formula manufacturers as well as requirements and recommendations for achieving compliance with all U.S. requirements that apply to their products.

**For more information**

Enforcement Discretion to Manufacturers to Increase Infant Formula Supplies

                                                                                  Content current as of:
      01/09/2023
              
              
Regulated Product(s)
		 Food & Beverages
			  			     			  						              
			
			
			
			
			
						  Infant Formula & FoodsCFSAN Constituent Updates
 Subscribe to CFSAN Constituent Updates
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop